Overexpression FARSB Reveals Poor Prognosis in Breast Cancer and is Correlated with Immunity.

BACKGROUND

FARSB is a β-regulatory subunit of phenylalanine tRNA synthetase. It is reported that FARSB was involved in cancer progression. However, the molecular function of FARSB in breast cancer was unclear. This study aimed to investigate the prognostic significance of FARSB expression and its relationship with immunity in breast cancer.

METHODS

Several databases, including TCGA, HPA, and UALCAN database, were applied to study FARSB mRNA and protein expression and its association with aggressiveness in breast cancer. We used immunohistochemical staining (IHC) to study FARSB expression in breast cancer and normal tissues. Chi square test was explored to study the correlation between FARSB expression and clinical features in breast cancer. Kaplan-Meier analysis and Cox regression were utilized to discuss the prognosis of breast cancer. Spearman analysis was applied to analyze the association between FARSB expression and immunity. We studied the correlation of FARSB with common breast cancer chemotherapeutic drugs. We conducted GO, KEGG, and GSEA enrichment analysis to study the molecular function of FARSB in breast cancer.

RESULTS

The TCGA database suggested that FARSB was increased in several cancers, including breast cancer. HPA and UALCAN databases suggested that FARSB protein expression was higher in breast cancer than normal tissues. IHC analysis also confirmed the higher expression of FARSB in breast cancer. FARSB expression had correlation with ER status and PR status. In TCGA database, FARSB expression was related to ER status, PR status, and PAM50. Overexpression FARSB had adverse prognosis, and Cox regression considered FARSB as a prognostic marker. Immunological analysis demonstrated that FARSB was linked with immune cell infiltration and immune checkpoints. High FARSB expression had low TIDE score. In addition, FARSB was linked to drugs, such as 5-fluorouracil, doxorubicin, gemcitabine, and paclitaxel. GSEA analysis suggested that FARSB was involved in the pathways, including cell cycle, aminoacyl TRNA biosynthesis, DNA replication, spliceosome, and mismatch repair.

CONCLUSION

FARSB was highly expression at mRNA and protein level in breast cancer. Overexpression of FARSB had a poor prognosis in breast cancer. FARSB expression was associated with immunity and acted as a new target for cancer immunological therapy.